No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
MLYS Mineralys Therapeutics
- 12.340
- +0.510+4.31%
Close Dec 20 16:00 ET
- 12.340
- 0.0000.00%
Post 16:13 ET
614.15MMarket Cap-4.01P/E (TTM)
12.500High11.550Low512.66KVolume11.730Open11.830Pre Close6.23MTurnover1.90%Turnover RatioLossP/E (Static)49.77MShares16.90552wk High2.59P/B333.84MFloat Cap7.86552wk Low--Dividend TTM27.05MShs Float21.980Historical High--Div YieldTTM8.03%Amplitude5.850Historical Low12.148Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Q3 2024 Mineralys Therapeutics Inc Earnings Call
Mineralys Therapeutics | 8-K: Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Mineralys Therapeutics | 10-Q: Q3 2024 Earnings Report
Wells Fargo Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Announces Target Price $26
Buy Rating on Mineralys Therapeutics Driven by Lorundrostat's Potential in Hypertension Treatment
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Hookipa Pharma (HOOK)
Heat List
US
Overall
Symbol
Price
% Chg
No Data